A Clinical Study to Assess the Efficacy and Safety of Leriglitazone in Adult Male Subjects With Cerebral Adrenoleukodystrophy

Key Inclusion Criteria:

• Subject is male and aged ≥18 years.

• Subject has progressive cALD, defined as GdE+ brain lesions.

• Subjects for whom HSCT is not recommended by the investigator or subject is notwilling to undergo HSCT.

• Subject has a Loes score ≥0.5 and ≤12 at Screening.

• Subject does not have major functional disability in the Major FunctionalDisabilities-Neurological Function Score (MFD-NFS), except for "wheelchair bound" or "total incontinence", which will be allowed as these are considered expectedsymptoms of AMN in the time course of the disease

• Subject does not have major cognitive impairment which would impair his ability totake part in the study as determined by the investigator at screening.

Key Exclusion Criteria:

• Subject who had previous bone marrow transplantation (HSCT) or treatment withex-vivo gene therapy (eli-Cel).

• Subject has known type 1 or type 2 diabetes.

• Subject has known hypersensitivity or intolerance to pioglitazone or any otherthiazolidinedione.

• Subject is taking or has taken honokiol, pioglitazone, or other thiazolidinedioneswithin 3 months prior to Screening.

• Subject with current participation in another interventional clinical study orwithin 1 month prior to Screening.

• Subject with other medical, neuropsychiatric or social conditions that, in theopinion of the investigator, are likely to adversely affect the risk-benefit ofstudy participation, interfere with study compliance, or confound the study results.